H.C. Wainwright Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $73
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Regeneron (REGN)
Earnings Preview: RVMD to Report Financial Results Post-market on May 07
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $76
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $59 to $76
Sector Update: Health Care Stocks Swing Between Small Gains, Losses
Revolution Medicines Shares up 6% After Presenting Initial RMC-9805 Study Data
Revolution Medicines Shares Rise on 'Encouraging' Phase 1 Lung Cancer Trial Data
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?
Express News | Wedbush Reiterates Outperform on Revolution Medicines, Maintains $67 Price Target
S&P 500 Futures Drop In Premarket Trading; McCormick Vtg, TPG Lag
Market-Moving News for April 28th
Revolution Medicines Reports Promising Clinical Data for Zoldonrasib in KRAS G12D Mutant Non-Small Cell Lung Cancer at AACR Annual Meeting
Revolution Medicines Presents Initial Data From Zoldonrasib (RMC-9805) Study in Patients With KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
Express News | Revolution Medicines Presents Initial Data From Zoldonrasib (Rmc-9805) Study in Patients With Kras G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
Barclays Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $72
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), UnitedHealth (UNH) and Edwards Lifesciences (EW)
Barbara Weber, M.D., Elected to ITM Supervisory Board
Needham Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $59
Express News | Needham Reiterates Buy on Revolution Medicines, Maintains $59 Price Target